Smart, Innovative, Continuous: REMAP-CAP Launches First Video

9 November 2020

REMAP-CAP, an Adaptive Platform Trial for Community-Acquired Pneumonia, launched its first in a series of videos. The video shows the uniqueness, smart, and easy-to-handle design of this trial. As an adaptive platform, REMAP-CAP is designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment.

Combatting antimicrobial resistance – COMBACTE – battles antimicrobial resistance by speeding up the development of new antibiotics. CLIN-Net, the clinical network pillar of COMBACTE, is involved in the site selection of the REMAP-CAP trial and aims to select 250 hospitals across Europe.

Since the COVID-19 outbreak, REMAP-CAP has extended its domains to investigate new treatments specifically for COVID-19 patients on the ICU and the ward. With the ability to improve the design according to new insights and already having the clinical trial infrastructure in place to implement these insights swiftly, various interventions can be tested simultaneously within multiple therapeutic domains.


Video & more info

Share this post

Share on twitter
Share on linkedin
Share on facebook
Share on email